Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response

Thymidine Kinase ◽

Hormone Receptor ◽

Metastatic Breast ◽

Thymidine Kinase 1 ◽

Safety And Efficacy ◽

Alternative Schedule ◽

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1562 ◽

2021 ◽

Author(s):

Costanza Paoletti ◽

William E. Barlow ◽

Erin F. Cobain ◽

Mattias Bergqvist ◽

Rita S. Mehta ◽

...

Keyword(s):

Breast Cancer ◽

Thymidine Kinase ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Thymidine Kinase 1 ◽

First Line ◽

Abstract PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial

10.1158/1538-7445.sabcs20-ps2-04 ◽

2021 ◽

Author(s):

Costanza Paoletti ◽

William E. Barlow ◽

Mattias Bergqvist ◽

Rita S. Mehta ◽

Julie R. Gralow ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Hormone Receptor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Thymidine Kinase 1 ◽

First Line ◽

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy

Oncotarget ◽

10.18632/oncotarget.24700 ◽

2018 ◽

Vol 9 (23) ◽

pp. 16389-16399 ◽

Cited By ~ 16

Author(s):

Martina Bonechi ◽

Francesca Galardi ◽

Chiara Biagioni ◽

Francesca De Luca ◽

Mattias Bergqvist ◽

...

Keyword(s):

Breast Cancer ◽

Thymidine Kinase ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Thymidine Kinase 1 ◽

Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer

10.1158/1538-7445.sabcs17-ot1-03-06 ◽

2018 ◽

Cited By ~ 1

Author(s):

E Shagisultanova ◽

J Diamond ◽

A Stopeck ◽

L Pusztai ◽

R O'Regan ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Safety And Efficacy ◽

Phase Ib ◽

Abstract P5-06-11: Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC)

10.1158/1538-7445.sabcs19-p5-06-11 ◽

2020 ◽

Author(s):

Luca Malorni ◽

Ilenia Migliaccio ◽

Chiara Biagioni ◽

Lorenzo Rossi ◽

Irene De Santo ◽

...

Keyword(s):

Breast Cancer ◽

Thymidine Kinase ◽

Prognostic Marker ◽

Hormone Receptor ◽

Premenopausal Women ◽

Operable Breast Cancer ◽

Thymidine Kinase 1 ◽

Role of serum thymidine kinase-1 (TK1) activity in patients (pts) with hormone receptor positive (HR+) advanced breast cancer (ABC) treated with endocrine therapy (ET) in the EFECT trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.12031 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 12031-12031 ◽

Cited By ~ 1

Author(s):

Luca Malorni ◽

Chiara Biagioni ◽

Amelia McCartney ◽

Gaia Schiavon ◽

Mattias Bergqvist ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Thymidine Kinase ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

Thymidine Kinase 1 ◽

292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.575 ◽

2021 ◽

Vol 32 ◽

pp. S492

Author(s):

L. Malorni ◽

M. De Laurentiis ◽

G. Bianchini ◽

A. Zambelli ◽

F. Puglisi ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Thymidine Kinase ◽

Hormone Receptor ◽

Advanced Breast ◽

Thymidine Kinase 1 ◽

First Line ◽

OT1-02-03: EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) in Combination with Lapatinib (L), Trastuzumab (T) or Both for the Treatment of Hormone Receptor-Positive (HR+), HER2+ Metastatic Breast Cancer (MBC).

10.1158/0008-5472.sabcs11-ot1-02-03 ◽

2011 ◽

Author(s):

S Johnston ◽

M Leigh ◽

A Florance ◽

S Wroblewski ◽

W Gradishar

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Metastatic Breast ◽

Safety And Efficacy ◽

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)

European Journal of Cancer ◽

10.1016/j.ejca.2019.04.002 ◽

2019 ◽

Vol 114 ◽

pp. 55-66 ◽

Cited By ~ 7

Author(s):

Amelia McCartney ◽

Chiara Biagioni ◽

Gaia Schiavon ◽

Mattias Bergqvist ◽

Karin Mattsson ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

Phase Iii ◽

Prognostic Role ◽

Thymidine Kinase 1 ◽

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04060862 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽